$DYAI
DYADIC INTERNATIONAL INC Stock $dyai

$dyai Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000143774922007554 Filed on March 29, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$2.404M	$350.0K	$1.602M
YoY Change	50.06%	-18.6%	-4.71%
Cost Of Revenue	$1.944M	$260.0K	$1.425M
YoY Change	36.46%	-38.1%	-2.38%
Gross Profit	$459.4K	$90.00K	$177.0K
YoY Change	159.56%	800.0%	-20.05%
Gross Profit Margin	19.11%	25.71%	11.05%
Selling, General & Admin	$6.698M	$1.310M	$6.080M
YoY Change	10.16%	12.93%	10.14%
% of Gross Profit	1457.93%	1455.56%	3435.22%
Research & Development	$8.392M	$1.010M	$3.868M
YoY Change	116.96%	29.49%	25.28%
% of Gross Profit	1826.84%	1122.22%	2185.5%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$8.392M	$2.310M	$3.868M
YoY Change	116.96%	18.46%	25.28%
Operating Profit	-$14.73M	-$2.220M	-$10.03M
YoY Change	46.9%	14.43%	8.01%
Interest Expense	$51.70K	$300.0K	$447.0K
YoY Change	-88.43%	42.86%	-54.62%
% of Operating Profit
Other Income/Expense, Net	$1.657M		$731.7K
YoY Change	126.49%
Pretax Income	-$13.12M	-$1.930M	-$9.246M
YoY Change	41.85%	11.56%	11.74%
Income Tax	$0.00	$30.00K	$31.32K
% Of Pretax Income
Net Earnings	-$13.07M	-$1.960M	-$9.325M
YoY Change	40.16%	12.64%	12.24%
Net Earnings / Revenue	-543.73%	-560.0%	-582.13%
Basic Earnings Per Share	-$0.47
Diluted Earnings Per Share	-$469.5K	-$71.30K	-$339.6K
COMMON SHARES
Basic Shares Outstanding		27.48M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.26M	$29.09M	$29.09M
YoY Change	-30.35%	-14.99%	-14.99%
Cash & Equivalents	$15.75M	$20.64M	$20.64M
Short-Term Investments	$4.512M	$8.460M	$8.460M
Other Short-Term Assets	$375.8K	$280.0K	$280.0K
YoY Change	34.23%	180.0%	180.0%
Inventory
Prepaid Expenses
Receivables	$277.8K	$294.2K	$290.0K
Other Receivables	$94.38K	$120.0K	$120.0K
Total Short-Term Assets	$21.01M	$29.78M	$29.78M
YoY Change	-29.46%	-16.44%	-16.44%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$284.7K	$280.0K	$280.0K
YoY Change	1.68%	-81.46%	-81.46%
Other Assets	$6.120K	$6.225K	$10.00K
YoY Change	-38.8%	-87.87%	-80.0%
Total Long-Term Assets	$290.8K	$290.9K	$290.0K
YoY Change	0.28%	-83.96%	-83.98%
TOTAL ASSETS
Total Short-Term Assets	$21.01M	$29.78M	$29.78M
Total Long-Term Assets	$290.8K	$290.9K	$290.0K
Total Assets	$21.30M	$30.07M	$30.07M
YoY Change	-29.17%	-19.71%	-19.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.013M
YoY Change		7.39%
Accrued Expenses	$709.6K	$489.8K	$490.0K
YoY Change	44.81%	-13.47%	-14.04%
Deferred Revenue		$123.0K
YoY Change		56.42%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.556M	$1.626M	$1.630M
YoY Change	56.79%	2.38%	2.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$352.9K
YoY Change
Total Long-Term Liabilities	$352.9K	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.556M	$1.626M	$1.630M
Total Long-Term Liabilities	$352.9K	$0.00	$0.00
Total Liabilities	$2.909M	$1.626M	$1.630M
YoY Change	78.45%	2.26%	2.52%
SHAREHOLDERS EQUITY
Retained Earnings		-$50.68M
YoY Change		22.55%
Common Stock		$39.75K
YoY Change		0.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$18.93M
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity	$18.39M	$28.45M	$28.45M
YoY Change
Total Liabilities & Shareholders Equity	$21.30M	$30.07M	$30.07M
YoY Change	-29.17%	-19.71%	-19.71%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$13.07M	-$1.960M	-$9.325M
YoY Change	40.16%	12.64%	12.24%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$11.28M	-$1.280M	-$6.574M
YoY Change	71.53%	-8.57%	13.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$5.222M	$40.00K	$22.12M
YoY Change	-76.39%	-97.01%	186.9%
Cash From Investing Activities	$5.222M	$40.00K	$22.12M
YoY Change	-76.4%	-97.01%	187.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.230M	30.00K	$255.5K
YoY Change	381.49%	-86.36%	-53.57%
NET CHANGE
Cash From Operating Activities	-$11.28M	-1.280M	-$6.574M
Cash From Investing Activities	$5.222M	40.00K	$22.12M
Cash From Financing Activities	$1.230M	30.00K	$255.5K
Net Change In Cash	-$4.889M	-1.210M	$15.81M
YoY Change	-130.91%	-856.25%	548.83%
FREE CASH FLOW
Cash From Operating Activities	-$11.28M	-$1.280M	-$6.574M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40482659
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39747659
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28229157
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27494157
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021	dyai	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	0	USD
CY2017Q2	dyai	Collaborative Arrangement Payment For Research And Development Agreement CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement	1000000.0	EUR
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18900000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15748480	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20637045	USD
CY2021Q4	dyai	Deferred License Revenue Net Of Current Portion DeferredLicenseRevenueNetOfCurrentPortion	352941	USD
CY2020Q4	dyai	Deferred License Revenue Net Of Current Portion DeferredLicenseRevenueNetOfCurrentPortion	0	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	4511780	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	8457452	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	94375	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021	dei	Auditor Location AuditorLocation	St. Petersburg, FL
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	112247	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	29781498	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	277831	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	294199	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	375830	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	280555	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21008296	USD
CY2021Q4	dyai	Prepaid Research And Development In Process Current PrepaidResearchAndDevelopmentInProcessCurrent	284709	USD
CY2020Q4	dyai	Prepaid Research And Development In Process Current PrepaidResearchAndDevelopmentInProcessCurrent	284709	USD
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6117	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6225	USD
CY2021Q4	us-gaap	Assets Assets	21299122	USD
CY2020Q4	us-gaap	Assets Assets	30072432	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1547953	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1013099	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	709560	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	489756	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	151147	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	123016	USD
CY2021Q4	dyai	Deferred License Revenue Current DeferredLicenseRevenueCurrent	147059	USD
CY2020Q4	dyai	Deferred License Revenue Current DeferredLicenseRevenueCurrent	0	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2555719	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1625871	USD
CY2021Q4	us-gaap	Liabilities Liabilities	2908660	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1625871	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	284709	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1657236	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	731708	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	40483	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	39748	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101026496	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	98013079	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18929915	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18929915	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63746602	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50676351	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18390462	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28446561	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21299122	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30072432	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2403831	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1601921	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1944438	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1424931	USD
CY2021	dyai	Provision For Contract Losses ProvisionForContractLosses	0	USD
CY2020	dyai	Provision For Contract Losses ProvisionForContractLosses	187388	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8392370	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3868121	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6697617	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6084799	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-96893	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-62345	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	17131318	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	11627584	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-14727487	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-10025663	USD
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	51704	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	446999	USD
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1605532	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-13070251	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-9293955	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31318	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13070251	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9325273	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27838047
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27471587
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	35864471	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1651893	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	255470	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9325273	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28446561	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1784102	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1230050	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13070251	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18390462	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13070251	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9325273	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1784102	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1651893	USD
CY2021	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	329612	USD
CY2020	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	331277	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-0	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	284709	USD
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1605532	USD
CY2020	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-0	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-96893	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-62345	USD
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-17872	USD
CY2020	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-217464	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4823544	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31792	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-363365	USD
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-0	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-500616	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95366	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2410	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	549562	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-53200	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	219824	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-80132	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	500000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	28131	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	44372	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11276945	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6574392	USD
CY2021	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	11283940	USD
CY2020	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	17638947	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	14900000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	39761000	USD
CY2021	dyai	Proceeds From Sale Of Investment In Bdi ProceedsFromSaleOfInvestmentInBDI	1605532	USD
CY2020	dyai	Proceeds From Sale Of Investment In Bdi ProceedsFromSaleOfInvestmentInBDI	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5221592	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22122053	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1230050	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	255470	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1230050	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	255470	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-63262	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10370	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4888565	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15813501	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20637045	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15748480	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20637045	USD
CY2021	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2020	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	500616	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	277831	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	294199	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">For each of the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s revenue was generated from fourteen customers. As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s accounts receivable was from eight and nine customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company had eight and seven customers outside of the United Sates (i.e. European and Asian customers) that accounted for approximately $1,716,000 or 71.3% and $796,000 or 49.7% of total revenue, respectively. As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company had four and seven customers outside of the United Sates (i.e. European and Asian customers) that accounted for approximately $157,000 or 56.4% and $123,000 or 41.6% of accounts receivable, respectively.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. For the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em>, three and one CRO(s) accounted for approximately $9,061,000 or 95.1% and $4,576,000 or 91.6% of total research services we purchased, respectively. As of <em style="font: inherit;"> December 31, 2021</em>, two CROs accounted for approximately $1,312,000 or 84.8% of accounts payable. As of <em style="font: inherit;"> December 31, 2020</em>, one CRO accounted for approximately $690,000 or 68.1% of accounts payable. The loss of business from this CRO or a combination of the Company’s CROs could adversely affect its operations.</p>
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	326712	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	204988	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	45839	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	72403	USD
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3279	USD
CY2020Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3164	USD
CY2020Q4	dyai	Accrued Research And Development In Process Current AccruedResearchAndDevelopmentInProcessCurrent	28508	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	109552	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13367	USD
CY2020	dyai	Research And Development Expense Personnel Related Costs ResearchAndDevelopmentExpensePersonnelRelatedCosts	531405	USD
CY2021	dyai	Research And Development Expense Facilities Overhead And Other ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther	116007	USD
CY2020	dyai	Research And Development Expense Facilities Overhead And Other ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther	34682	USD
CY2021	dyai	Research And Development Expense Including Related Party ResearchAndDevelopmentExpenseIncludingRelatedParty	8392370	USD
CY2020	dyai	Research And Development Expense Including Related Party ResearchAndDevelopmentExpenseIncludingRelatedParty	3868121	USD
CY2021Q4	dyai	Research And Development In Process Current ResearchAndDevelopmentInProcessCurrent	1363889	USD
CY2020Q4	dyai	Research And Development In Process Current ResearchAndDevelopmentInProcessCurrent	904572	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	27675	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	24496	USD
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	156389	USD
CY2020Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	84031	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1547953	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1013099	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	405758	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	447881	USD
CY2021Q4	dyai	Accrued Research And Development In Process Current AccruedResearchAndDevelopmentInProcessCurrent	194250	USD
CY2021	dyai	Research And Development Expense Outside Contracted Services ResearchAndDevelopmentExpenseOutsideContractedServices	7607035	USD
CY2020	dyai	Research And Development Expense Outside Contracted Services ResearchAndDevelopmentExpenseOutsideContractedServices	3302034	USD
CY2021	dyai	Research And Development Expense Personnel Related Costs ResearchAndDevelopmentExpensePersonnelRelatedCosts	669328	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2419	pure
CY2021	dyai	Effective Income Tax Rate Reconciliation Trueup Adjustment Percent EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent	0.0006	pure
CY2020	dyai	Effective Income Tax Rate Reconciliation Trueup Adjustment Percent EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent	0.0133	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0009	pure
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4774215
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4638390
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0452	pure
CY2021Q4	us-gaap	Cash Cash	1377094	USD
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	14371386	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	15748480	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15748480	USD
CY2021Q4	dyai	Cash Cash Equivalents And Investments Fair Value CashCashEquivalentsAndInvestmentsFairValue	20257765	USD
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	USD
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	2495	USD
CY2021Q4	us-gaap	Investments And Cash InvestmentsAndCash	20260260	USD
CY2020Q4	us-gaap	Cash Cash	149015	USD
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	20488030	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	20637045	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20637045	USD
CY2020Q4	dyai	Cash Cash Equivalents And Investments Fair Value CashCashEquivalentsAndInvestmentsFairValue	29110506	USD
CY2020Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	22473	USD
CY2020Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	6463	USD
CY2020Q4	us-gaap	Investments And Cash InvestmentsAndCash	29094496	USD
CY2021Q4	dyai	Upfront Payment Payable UpfrontPaymentPayable	500000	USD
CY2021Q4	dyai	Number Of Performance Obligations NumberOfPerformanceObligations	2	pure
CY2017Q2	dyai	Collaborative Arrangement Payment For Research And Development Agreement CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement	1100000	USD
CY2021	dyai	Tax Cuts And Jobs Act Change In Alternative Minimum Tax Income Tax Benefit TaxCutsAndJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit	1001233	USD
CY2018	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	500000	USD
CY2019	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	500000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13115869	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9246122	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	45618	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-47833	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-13070251	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-9293955	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0360	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0084	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0045	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2809	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0013	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0188	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0034	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	947400	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	689600	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10509900	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7080600	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1656500	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1656500	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	72100	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	69800	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-6100	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7900	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13035600	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9364800	USD
CY2021Q4	dyai	Deferred Tax Assets Net Of Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance	13035600	USD
CY2020Q4	dyai	Deferred Tax Assets Net Of Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance	9364800	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	39900000	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	27300000	USD
CY2021Q4	dyai	Operating Loss Carryforwards Will Be Carried Forward Indefinitely OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely	37100000	USD
CY2021Q4	dyai	Operating Loss Carryforwards Will Be Carried Forward Indefinitely Available To Offset Taxable Income Percentage OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage	0.80	pure
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	2617601	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	374689	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	327041	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	3319331	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3860390
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.76
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M8D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13287932	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	913000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.24
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	135000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.89
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4638390
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.44
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M20D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13701610	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	870825
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18900000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.11
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	735000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4774215
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M20D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8413444	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3384516
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.45
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M15D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	7674636	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.49
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.09
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1729850	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	481139	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	856982	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	477232	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y25D
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M2D
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1784102	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1651893	USD
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.89
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502

Files In Submission

Name	View Source	Status
0001437749-22-007554-index-headers.html	Edgar Link	pending
0001437749-22-007554-index.html	Edgar Link	pending
0001437749-22-007554.txt	Edgar Link	pending
0001437749-22-007554-xbrl.zip	Edgar Link	pending
dyai-20211231.xsd	Edgar Link	pending
dyai-20211231_cal.xml	Edgar Link	unprocessable
dyai-20211231_def.xml	Edgar Link	unprocessable
dyai-20211231_lab.xml	Edgar Link	unprocessable
dyai-20211231_pre.xml	Edgar Link	unprocessable
dyai20201008_10kimg001.jpg	Edgar Link	pending
dyai20211231_10k.htm	Edgar Link	pending
dyai20211231_10k_htm.xml	Edgar Link	completed
ex_311121.htm	Edgar Link	pending
ex_311122.htm	Edgar Link	pending
ex_311123.htm	Edgar Link	pending
ex_311124.htm	Edgar Link	pending
ex_311125.htm	Edgar Link	pending
ex_342547.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img.jpg	Edgar Link	pending
img2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mhm01.jpg	Edgar Link	pending
mhm02.jpg	Edgar Link	pending
mhm03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DYAI
DYADIC INTERNATIONAL INC Stock $dyai

2021 Form 10-K Financial Statement

#000143774922007554 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DYAI DYADIC INTERNATIONAL INC Stock $dyai

2021 Form 10-K Financial Statement

#000143774922007554 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DYAI
DYADIC INTERNATIONAL INC Stock $dyai